Items Tagged ‘taxotere’

March 16th, 2015

Cyramza® plus Taxotere® Promising in Advanced Bladder Cancer

By

The treatment combination of Cyramza® (ramucirumab) plus Taxotere® (docetaxel) appears to extend progression-free survival in patients with advanced bladder cancer that has relapse after previous treatment. These findings were presented at the 2015 Genitourinary Cancers Symposium on February 26–28 in Orlando, Florida. Bladder cancer is diagnosed in roughly 50,000 men and 17,000 women annually in […]

View full entry

Tags: Bladder Cancer, cyramza, News, Recurrent Bladder Cancer, Stage IV/Metastatic Bladder Cancer, taxotere


November 6th, 2014

Xofigo Extends Survival in Hormone-Refractory Prostate Cancer

By

For patients with advanced hormone-refractory prostate cancer, the agent Xofigo® (radium-223) appears similarly effective in patients who have and have not received Taxotere® (docetaxel), a chemotherapy drug that can be used in the treatment of advanced prostate cancer. These findings were recently published in The Lancet Oncology. Prostate cancer is a hormonally sensitive disease that […]

View full entry

Tags: Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, radium-223, Refactory/Recurrent Prostate Cancer, taxotere, xofigo


June 3rd, 2014

Taxotere Added to Hormone Therapy Improves Overall Survival by 13 Months in Metastatic Prostate Cancer Patients

By

In a study conducted by researchers at the Dana-Farber Cancer Institute, Taxotere® (docetaxel) administered with androgen-deprivation therapy to metastatic prostate cancer patients was found to extend overall survival by more than 13 months. The results were reported at the 2014 American Society of Clinical Oncology (ASCO) meeting held in Chicago. Prostate cancer occurs when the […]

View full entry

Tags: asco, docetaxel, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, Refactory/Recurrent Prostate Cancer, taxotere